Amesite

AMST

Capitalización de mercado USD 5.46 M

Company Estimates Agreements at New Pricing Level Can Generate Approximately 85% Gross Margin, Supporting Scalable Growth Across Post-Acute Care Organizations Company Estimates Agreements at New Pricing Level Can Generate Approximately 85% Gross Margin, Supporting Scalable Growth Across Post-Acute Care Organizations

Enterprise Deployment Validates AI-Native Infrastructure Strategy and Proves Scalable, Cost-Efficient Execution in Non-Acute Care Enterprise Deployment Validates AI-Native Infrastructure Strategy and Proves Scalable, Cost-Efficient Execution in Non-Acute Care

$2.6 million upfront with up to approximately $5.2 million of potential aggregate proceeds upon the exercise in full of warrants $2.6 million upfront with up to approximately $5.2 million of potential aggregate proceeds upon the exercise in full of warrants

DETROIT, April 28, 2026 (GLOBE NEWSWIRE) -- Amesite Inc. (Nasdaq: AMST), developer of the AI‑native NurseMagic™ platform and EMR for non‑acute care, today announced that it has entered into definitive agreements with certain of its officers and directors, including Dr. Ann Marie Sastry, Ph.D, its Chairman and CEO, and George Parmer, a member of its board of directors, for the purchase and sale of an aggregate of 418,118 shares of its common stock, Series A-1 warrants to purchase an aggregate up to 418,118 shares of the Company's common stock and Series A-2 warrants to purchase an aggregate up to 418,118 shares of the Company's common stock at a purchase price of $1.435 per share and accompanying warrants. The private placement follows the Company's recently announced concurrent registered direct offering and private placement, priced at-the-market under Nasdaq rules, which is expected to result in aggregate gross proceeds to the Company of approximately $2 million, before deducting placement agent fees and other offering expenses.

DETROIT, April 27, 2026 (GLOBE NEWSWIRE) -- Amesite Inc. (Nasdaq: AMST), developer of the AI‑native NurseMagic™ platform and EMR for non‑acute care, today announced that it has entered into definitive agreements for the purchase and sale of 696,866 shares of its common stock, at a purchase price of $1.435 per share in a registered direct offering priced at-the-market under Nasdaq rules. In addition, the Company has agreed to issue to the investor unregistered Series A-1 warrants to purchase up to 696,866 shares of common stock and unregistered Series A-2 warrants to purchase up to 696,866 shares of common stock.

DETROIT, April 27, 2026 (GLOBE NEWSWIRE) -- Amesite Inc. (Nasdaq: AMST) (the “Company”), a leading developer of AI-powered enterprise solutions, today announced that it has filed with the U.S. Securities and Exchange Commission (the “SEC”) a request for withdrawal of the Company's Registration Statement on Form S-1 (No. 333-295187) originally filed on April 20, 2026 (the “Registration Statement”), as the Company no longer intends to pursue a public offering under the Registration Statement at this time.

Agreement Enables HIPAA-Compliant Exchange of EVV Transactions with Company Processing Billions of Dollars in Homecare Services Billed Annually Agreement Enables HIPAA-Compliant Exchange of EVV Transactions with Company Processing Billions of Dollars in Homecare Services Billed Annually

AMST's recognition from one of the largest online nursing communities follows step-change revenue growth as company targets a post-acute market expected to exceed $800 billion AMST's recognition from one of the largest online nursing communities follows step-change revenue growth as company targets a post-acute market expected to exceed $800 billion

Company enters the infrastructure layer of post-acute care following sustained revenue expansion and enterprise adoption Company enters the infrastructure layer of post-acute care following sustained revenue expansion and enterprise adoption

Shareholder Update Reports Positive Customer Reviews, New Segment Growth and Technology Rollouts across Post-Acute Healthcare Shareholder Update Reports Positive Customer Reviews, New Segment Growth and Technology Rollouts across Post-Acute Healthcare